Background: Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have demonstrated cardiovascular benefit in patients with type 2 diabetes and, more recently, in obese adults without diabetes. The gene discussed is GCG; the disease is type 2 diabetes mellitus.